Der Kardiologe

, Volume 5, Issue 6, pp 463–478

Rhythmusstörungen bei Schwangeren

Was wann tun?
CME Weiterbildung · Zertifizierte Fortbildung


Supraventrikuläre Extrasystolen werden während einer Schwangerschaft (SWS) häufig beobachtet, supraventrikuläre Tachykardien eher seltener. Zur Akuttherapie (AT) ist bei hämodynamischer Instabilität (HI) eine elektrische Kardioversion (KV) mit 50–100 Joules notwendig. Bei stabiler Hämodynamik (SH) sollten primär vagale Manöver durchgeführt werden, bei Versagen vagaler Maßnahmen ist Adenosin das Medikament der 1. Wahl. Für die Langzeittherapie (LZ-T) kommen v. a. β1-selektive β-Blocker (BB) infrage, seltener spezifische Antiarrhythmika (AA) der Klassen Ic oder der Klasse III [Sotalol (Sot)]. Ventrikuläre Extrasystolen sind während einer SWS ebenfalls relativ häufig und bei den meisten Patientinnen harmlos, maligne ventrikuläre Arrhythmien [ventrikuläre Tachykardien (KT), Kammerflattern (KFlat), Kammerflimmern (KF)] werden dagegen eher seltener beobachtet. Als AT sollte bei HI eine elektrische KV erfolgen, bei SH kommen Ajmalin, Procainamid oder Lidocain in Betracht. Für die LZ-T sollten primär β1-selektive BB eingesetzt werden, bei Therapierefraktärität spezifische AA der Klasse Ic oder Sot. Für Patientinnen mit synkopaler KT, KF, KFlat oder überlebtem plötzlichem Tod ist der implantierbare Defibrillator eine therapeutische Alternative. Bei Patientinnen mit symptomatischen Bradykardien kann ein Schrittmachersystem implantiert werden. Trotz notwendiger Besonderheiten im therapeutischen Verhalten während einer SWS können alle supraventrikulären und/oder ventrikulären Arrhythmien adäquat behandelt und auch komplizierte Schwangerschaften erfolgreich beendet werden. Auch in der Stillzeit können zahlreiche Antiarrhythmika ohne Probleme angewendet werden.


Herzrhythmusstörungen Schwangerschaft Stillzeit Plötzlicher Tod Antiarrhythmika 

The pregnant woman with arrhythmias

What to do when?


Atrial premature beats are frequently diagnosed during pregnancy (PR) and supraventricular tachycardia (SVT) (atrial tachycardia, AV nodal reentrant tachycardia, circus movement tachycardia) less frequently. For acute therapy, electrical cardioversion with 50–100 J is indicated in all unstable patients. In stable SVT the initial therapy includes vagal maneuvers to terminate breakthrough tachycardias. For short-term management, when vagal maneuvers fail, intravenous adenosine is the first choice drug and may safely terminate the arrhythmia. For long-term therapy, ß-blocking agents with β1 selectivity are first-line drugs; class Ic agents or the class III drug sotalol (sot) are effective and therapeutic alternatives. Ventricular premature beats are also frequently present during PR and benign in most of the patients; however, malignant ventricular tachyarrhythmias [sustained ventricular tachycardia (VT), ventricular flutter (VFlut), ventricular fibrillation (VF)] were observed less frequently. Electrical cardioversion is necessary in all patients with hemodynamically unstable situation and life-threatening ventricular tachyarrhythmias; in hemodynamically stable patients, initial therapy with ajmaline, procainamide or lidocaine is indicated. If prophylactic therapy is needed, ß-blocking agents with ß1 selectivity are considered as first choice drugs. If this therapy is ineffective, class Ic agents or sot can be considered. In patients with syncopal VT, VF, VFlut or aborted sudden death an implantable cardioverter-defibrillator is indicated. In patients with symptomatic bradycardia, a pacemaker can be implanted using echocardiography at any stage of PR. The treatment of the pregnant patient with cardiac arrhythmias requires important modification of the standard practice of arrhythmia management. The goal of therapy is to protect the patient and fetus through delivery, after which chronic or definitive therapy can be administered. In addition, antiarrhythmic therapy is also possible during breastfeeding.


Cardiac arrhythmias Pregnancy Breastfeeding Sudden death Antiarrhythmic drugs 


  1. 1.
    American Academy of Pediatrics, Committee on Drugs (1994) The transfer of drugs and other chemicals into human breast milk. Pediatrics 93:137–150Google Scholar
  2. 2.
    Bravermann AC, Bromley BS, Rutherford JD (1991) New onset ventricular tachycardia during pregnancy. Int J Cardiol 33:409–412CrossRefGoogle Scholar
  3. 3.
    Brodsky M, Doria R, Allen B et al (1992) New-onset ventricular tachycardia during pregnancy. Am Heart J 123:933–941PubMedCrossRefGoogle Scholar
  4. 4.
    Camm AJ et al (2010) Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 31:2369–2429PubMedCrossRefGoogle Scholar
  5. 5.
    Cardosi RJ, Chez RA (1998) Magnesium sulfate, maternal hypothermia, and fetal bradycardia with loss of heart rate variability. Obstet Gynecol 92:691–693PubMedCrossRefGoogle Scholar
  6. 6.
    Chow T, Galvin J, McGowern B (1998) Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 82:58I–62IPubMedCrossRefGoogle Scholar
  7. 7.
    Cleary-Goldmann J, Salva CR, Infeld JI, Robinson JN (2003) Verapamil-sensitive idiopathic left ventricular tachycardia in pregnancy. J Matern Fetal Neonatal Med 14:132–135CrossRefGoogle Scholar
  8. 8.
    Dalvi BV, Chaudhuri A, Kulkarni HL, Purushottam KA (1992) Therapeutic guidelines for congenital heart block presenting in pregnancy. Obstet Gynecol 79:802–804PubMedGoogle Scholar
  9. 9.
    Danielsson BR, Azarbayjani F, Skold AC, Webster WS (1997) Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation. Teratology 56:271–281PubMedCrossRefGoogle Scholar
  10. 10.
    Dominguez A, Iturralde P, Hermosillo AG et al (1999) Successful radiofrequency ablation of an accessory pathway during pregnancy. Pacing Clin Electrophysiol 22:131–134PubMedCrossRefGoogle Scholar
  11. 11.
    Dorian P, Cass D, Schwartz B et al (2002) Amiodarone as compared to Lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346:884–890PubMedCrossRefGoogle Scholar
  12. 12.
    Facchini M, Bauersfeld U, Fasnacht M, Candinas R (2000) Mütterliche Herzrhythmusstörungen während der Schwangerschaft. Schweiz Med Wochenschr 130:1962–1969PubMedGoogle Scholar
  13. 13.
    Ferrero S, Colombo BM, Ragni N (2004) Maternal arrhythmias during pregnancy. Arch Gynecol Obstet 269:244–253PubMedCrossRefGoogle Scholar
  14. 14.
    Finlay AY, Edmunds V (1979) DC cardioversion in pregnancy. Br J Clin Pract 33:88–94PubMedGoogle Scholar
  15. 15.
    Gowda RM, Khan IA, Mehta NJ et al (2003) Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int J Cardiol 88:129–133PubMedCrossRefGoogle Scholar
  16. 16.
    Gras D, Mabo P, Kermarrec A et al (1992) Radiofrequency ablation of atrioventricular conduction during the 5th month of pregnancy. Arch Mal Coeur Vaiss 85:1873–1877PubMedGoogle Scholar
  17. 17.
    Habib A, McCarthy JS (1977) Effects on the neonate of propranolol admininstered during pregnancy. J Pediatr 91:808–811PubMedCrossRefGoogle Scholar
  18. 18.
    Huang H, Lin Q, Zhang L (1997) Clinical observation of cardiac pacemaker in pregnant women. Chuang Hua Fu Chan Ko Tsa Chih 32:345–346Google Scholar
  19. 19.
    Isaacs JD, Mulholland DH, Hess LW et al (1993) Pregnancy in a woman with an automatic implantable cardioverter defibrillator: a case report. J Reprod Med 36:487–488Google Scholar
  20. 20.
    Joglar JA, Page RL (1999) Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf 20:85–94PubMedCrossRefGoogle Scholar
  21. 21.
    Klein HH, Pich S (2003) Physiologische Änderungen des Herz-Kreislauf-Systems in der Schwangerschaft. Herz 28:173–174PubMedCrossRefGoogle Scholar
  22. 22.
    Kudenchuk PJ, Cobb LA, Copass MK et al (1999) Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341:871–887PubMedCrossRefGoogle Scholar
  23. 23.
    Lau CP, Lee CP, Wong CK et al (1990) Rate responsive pacing with a minute ventilation sensing pacemaker during pregnancy and delivery. Pacing Clin Electrophysiol 13:158–163PubMedCrossRefGoogle Scholar
  24. 24.
    Lee SH, Chen SA, Wu TJ et al (1995) Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 76:675–678PubMedCrossRefGoogle Scholar
  25. 25.
    Lenz W (1961) Kindliche Fehlbildungen nach Medikament während der Gravidität? Dtsch Med Wochenschr 86:2555–2556Google Scholar
  26. 26.
    Magee LA, Downar E, Sermer M et al (1995) Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol 172:1307–1311PubMedCrossRefGoogle Scholar
  27. 27.
    McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 28:1358–1364CrossRefGoogle Scholar
  28. 28.
    Mitani GM, Steinberg I, Lien EJ et al (1987) The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet 12:253–291PubMedCrossRefGoogle Scholar
  29. 29.
    Mozo Rosales F de, Moreno J, Bodegas A et al (1994) Conversion of atrial fibrillation with ajmaline in a pregnant woman with Wolff-Parkinson-White syndrome. Eur J Obstet Gynecol 56:63–66CrossRefGoogle Scholar
  30. 30.
    Nakagawa M, Katou S, Ichinose M et al (2004) Characteristics of new-onset ventricular arrhythmias in pregnancy. J Electrocardiol 37:47–53PubMedCrossRefGoogle Scholar
  31. 31.
    Natale A, Davidson T, Geiger MJ, Newby K (1997) Implantable cardioverter-defibrillators and pregnancy. A safe combination? Circulation 96:2808–2812PubMedGoogle Scholar
  32. 32.
    Navarro V, Nathan PE, Rosero H, Sacchi TJ (1993) Accelerated idioventricular rhythm in pregnancy: a case report. Angiology 44:506–508PubMedCrossRefGoogle Scholar
  33. 33.
    Nolan JP, Soar J, Zideman DA et al (2010) European Resuscitation Council Guidelines for Resuscitation 2010. Section 1. Executive summary. Resuscitation 81:1219–1276PubMedCrossRefGoogle Scholar
  34. 34.
    Pagdad SV, Barmade AB, Toal SC et al (2004) Rescue radiofrequency ablation for atrial tachycardia presenting as cardiomyopathy in pregnancy. Indian Heart J 56:245–247Google Scholar
  35. 35.
    Page RL (1995) Treatment of arrhythmias during pregnancy. Am Heart J 130:871–876PubMedCrossRefGoogle Scholar
  36. 36.
    Page RL, Shenasa H, Evans J et al (1993) Radiofrequency catheter ablation of idiopathic recurrent ventricular tachycardia with a right bundle branch block, left axis pattern. Pacing Clin Electrophysiol 16:327–336PubMedCrossRefGoogle Scholar
  37. 37.
    Piper JM, Berkus M, Ridgway LE (1992) Pregnancy complicated by chronic cardiomyopathy and an automatic implantable cardioverter defibrillator. Am J Obstet Gynecol 167:506–507PubMedGoogle Scholar
  38. 38.
    Plomp TA, Vulsma T, Vijlder JJ de (1992) Use of amiodarone during pregnancy. Eur J Obstet Gynecol Reprod Biol 43:201–207PubMedCrossRefGoogle Scholar
  39. 39.
    Rahilly GT, Prystowsky EN, Zipes DP et al (1982) Clinical and electrophysiologic findings in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. Am J Cardiol 50:459–468PubMedCrossRefGoogle Scholar
  40. 40.
    Ramsewak S, Persad P, Perkins S, Narayansingh G (1992) Twin pregnancy in a patient with complete heart block. A case report. Clin Exp Obstet Gynecol 19:166–167PubMedGoogle Scholar
  41. 41.
    Regitz-Zagrosek V, Gohlke-Bärwolf C, Geibel-Zehender A et al (2008) Herzerkrankungen in der Schwangerschaft. Clin Res Cardiol 97:630–665PubMedCrossRefGoogle Scholar
  42. 42.
    Rotmensch HH, Elkayam U, Frishman W (1983) Antiarrhythmic drug therapy during pregnancy. Ann Intern Med 98:487–497PubMedGoogle Scholar
  43. 43.
    Schaefer C, Spielmann H (2001) Arzneiverordnung in Schwangerschaft und Stillzeit. Urban & Fischer, München Jena, S 2–26Google Scholar
  44. 44.
    Schaefer C, Spielmann H (2001) Spezielle Arzneimitteltherapie in der Stillzeit. In: Schaefer C, Spielmann (Hrsg) Arzneiverordnung in Schwangerschaft und Stillzeit. Urban & Fischer, München Jena, S 440–599Google Scholar
  45. 45.
    Schardein JL (2000) Chemically induced birth defects, 4. Aufl. Marcel Dekker, New YorkGoogle Scholar
  46. 46.
    Sermer M, Colman J, Siu S (2003) Pregnancy complicated by heart disease: a review of Canadian experience. J Obstet Gynaecol 23:540–544PubMedCrossRefGoogle Scholar
  47. 47.
    Shotan A, Ostrzega E, Mehra A et al (1997) Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 79:1061–1064PubMedCrossRefGoogle Scholar
  48. 48.
    Task Force Members, Oakley C, Child A, Iung B et al (2003) Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 24:761–781CrossRefGoogle Scholar
  49. 49.
    Trappe HJ (1997) Akuttherapie supraventrikulärer Tachykardien: Adenosin oder Ajmalin? Intensivmed 34:452–461CrossRefGoogle Scholar
  50. 50.
    Trappe HJ, Schuster HP (2000) Brugada-Syndrom. Definition, Diagnostik, Therapie, Prognose. Intensivmed 37:680–687CrossRefGoogle Scholar
  51. 51.
    Trappe HJ (2001) Amiodaron. Intensivmed 38:169–178CrossRefGoogle Scholar
  52. 52.
    Trappe HJ (2010) Konzept der „5A“ für die Intensiv- und Notfallmedizin. Kardiologe 4:43–54CrossRefGoogle Scholar
  53. 53.
    Varon ME, Sherer DM, Abramowicz JS, Akiyama T (1992) Maternal ventricular tachycardia associated with hypomagnesemia. Am J Obstet Gynecol 167:1352–1355PubMedGoogle Scholar
  54. 54.
    Wada H, Chiba Y, Murakami M et al (1996) Analysis of maternal and fetal risk in 594 pregnancies with heart disease. Nippon Sanka Fujinka Gakkai Zasshi 48:255–262PubMedGoogle Scholar
  55. 55.
    Warkany J, Nelson RC (1940) Appearance of skeletal abnormalities in the offspring of rats retarded on a deficient diet. Science 92:383–384PubMedCrossRefGoogle Scholar
  56. 56.
    Wellens HJJ, Conover B (2006) The ECG in emergency decision making. Chapter 1: Acute myocardial infarction, 2 Aufl. WB Saunders Company, Philadelphia, S 1–27Google Scholar
  57. 57.
    Widerhorn J, Widerhorn ALM, Rahimtoola SH, Elkayam U (1992) WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 123:796–798PubMedCrossRefGoogle Scholar
  58. 58.
    Wilson JD (1977) Embryotoxicity of drugs to man. In: Wilson JD, Frazer FC (Hrsg) Handbook of teratology. Plenum Press, New York, S 309–355Google Scholar
  59. 59.
    Wolbrette D (2003) Treatment of arrhythmias during pregnancy. Curr Womens Health Rep 3:135–139PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Medizinische Klinik II (Schwerpunkte Kardiologie und Angiologie)Ruhr-Universität BochumHerneDeutschland

Personalised recommendations